The rising burden of small vulnerable newborns in China: demanding targeted interventions
Affiliations & Notes
aSchool of Public Health, Xi'an Medical University, Xi'an, China
bDepartment of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
cKey Laboratory of Environment and Gene-Related Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, China
Article Info
Publication History:
Published February 18, 2026
DOI: 10.1016/S2214-109X(25)00529-7 External LinkAlso available on ScienceDirect External Link
Copyright: © 2025 The Author(s). Published by Elsevier Ltd.
Linked Articles
- Prevalence estimates of small vulnerable newborns in China (2012–22): a modelling studyThe Lancet Global HealthFebruary 18, 2026
Download started
OkThe latest WHO report indicates that there were 4·5 million maternal and newborn deaths globally in 2022. Of these, 1·9 million were stillbirths and 2·3 million were neonatal deaths (age <28 days), with nearly 60% occurring in low-income and middle-income countries.1 Infants born preterm (<37 weeks of gestation), small for gestational age (SGA), or who have low birthweight (LBW; <2500 g) have a substantially higher risk of maternal and child mortality;2 these conditions are collectively responsible for up to 80% of all neonatal deaths worldwide.3 In addition to the mortality risk, such infants remain susceptible to health problems across their lifespan, a cycle that often perpetuates across generations. Societally, there are human capital losses and wider societal effects such as socioeconomic development and burden of long-term care to health system and families.2,4 Despite the availability of effective interventions for preterm birth, LBW, and SGA,2,5,6 challenges in routine antenatal care have resulted in suboptimal progress in neonatal mortality reduction. In China, neonatal mortality has substantially declined from approximately 33·1 per 1000 livebirths in 1990 to 3·1 per 1000 livebirths in 2022.7,8 Despite outstanding progress in child survival, approximately 65 700 children younger than 5 years died in China in 2022, of whom 45·1% died in the neonatal period.8
In the 2023 Lancet Series, the Small Vulnerable Newborn Consortium proposed a new framework bringing together preterm birth, LBW, and SGA under the category small vulnerable newborn (SVN).2 This framework is designed to accelerate progress towards Sustainable Development Goal (SDG) 3.2, with the aim of ending preventable deaths of newborns and children younger than 5 years by 2030. However, limited research has adopted the unified definition to assess the burden of neonatal vulnerability in China,9 potentially resulting in an underestimation. China's evolving fertility policies and rising use of assisted reproductive technologies have increased the occurrence of high-risk pregnancies, advanced maternal age, multiparity, and multiple births, which elevate the risk of adverse birth outcomes. Accurate assessment of the SVN burden is essential to guide perinatal interventions, establish child health monitoring, and inform policies aimed at reducing neonatal mortality.
In The Lancet Global Health, Yanxia Xie and colleagues10 provide a comprehensive epidemiological analysis of SVNs in China, examining four mutually exclusive clinical subtypes (preterm non-SGA, preterm SGA, term SGA, and LBW only) nationwide and across 31 provinces between 2012 and 2022. The findings show that, in 2022, an estimated 13·2 per 100 liveborn newborns in mainland China were identified as SVNs. The national prevalence ratios (PRs) of SVNs remained stable overall between 2012 and 2022, with an observable turning point around 2018, when ratios began to increase after a previous decline. However, divergent trends emerged across subtypes. The PR of term SGA livebirths decreased, whereas the PRs of preterm non-SGA livebirths and LBW-only livebirths increased over the same period. Substantial geographical heterogeneity was also observed. In 2022, Qinghai had the highest PRs of SVN, preterm SGA, and term SGA livebirths, while Liaoning had the highest PR of preterm non-SGA livebirths and Chongqing had the highest PR of LBW-only livebirths. Temporally, Heilongjiang showed the most rapid increase in SVN prevalence, with Inner Mongolia showing the fastest growth in both preterm SGA and preterm non-SGA subtypes. Notably, SVNs accounted for more than 60% of in-hospital neonatal deaths and more than 80% of stillbirths, highlighting their severe public health burden. The substantial geographical heterogeneity in SVN prevalence and subtype distribution demands that prevention and resource allocation be calibrated to local epidemiological profiles.
Three research priorities emerge to address the rising burden of SVN births in China. At the national level, the immediate task is to investigate the drivers (eg, social determinants and maternal healthcare service quality) of the post-2018 rise in national SVN burden. This understanding is crucial to inform the shift from surveillance to the design and implementation of precise interventions. Second, shifting the focus to the SVN subtype level, the observed divergent trends across SVN subtypes indicate potential fundamental differences in their causal pathways. Therefore, clarifying distinct aetiological networks is essential to develop targeted interventions. Given that multiple micronutrient supplementation has been shown to reduce risks for both preterm SGA and term SGA,11 it warrants evaluation as a promising intervention to mitigate the rising burden of preterm-onset SVN. Third, at the spatial level, geographical diversity of SVNs at the provincial levels necessitates identifying modifiable local drivers, spanning health-care capacity, environmental exposures, socioeconomic status, and genetic factors, to guide context-specific interventions.
Xie and colleagues critically operationalise the 2023 Lancet SVN Series' global call to action within China by establishing the first national epidemiological profile of SVNs, thereby bridging a major knowledge gap and transitioning SVNs from a global priority to a national target. This study delivers a key policy message that the substantial provincial heterogeneity necessitates a shift to geographically tailored interventions, an imperative strategy for China to achieve SDG 3.2 and Healthy China 2030, thereby ending preventable under-5 deaths by 2030.
Competing Interests
We declare no competing interests.
References
1.
Thiruvengadam, R ∙ Ayushi ∙ Murugesan, DR ∙ et al.
Incidence of and risk factors for small vulnerable newborns in north India: a secondary analysis of a prospective pregnancy cohort
Lancet Glob Health. 2024; 12:e1261-e1277
2.
Ashorn, P ∙ Ashorn, U ∙ Muthiani, Y ∙ et al.
Small vulnerable newborns—big potential for impact
Lancet. 2023; 401:1692-1706
3.
Blencowe, H ∙ Krasevec, J ∙ de Onis, M ∙ et al.
National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis
Lancet Glob Health. 2019; 7:e849-e860
4.
Lawn, JE ∙ Blencowe, H ∙ Oza, S ∙ et al.
Every Newborn: progress, priorities, and potential beyond survival
Lancet. 2014; 384:189-205
5.
Hofmeyr, GJ ∙ Black, RE ∙ Rogozińska, E ∙ et al.
Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes
Lancet. 2023; 401:1733-1744
6.
Zeng, LX ∙ Dibley, MJ ∙ Cheng, Y ∙ et al.
Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial
Br Med J. 2008; 337, a2001
7.
Qiao, J ∙ Wang, Y ∙ Li, X ∙ et al.
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China
Lancet. 2021; 397:2497-2536
8.
He, C ∙ Kang, L ∙ Liu, Y ∙ et al.
Changes in the epidemiology of under-5 mortality in China from 2016 to 2022: an observational analysis of population-based surveillance data
Lancet Public Health. 2024; 9:e1059-e1069
9.
Zhao, Y ∙ Jia, Z ∙ Wang, L ∙ et al.
Trends in the incidence of high-risk newborns based on a new conceptual framework - Beijing Municipality, China, 2013–2022
China CDC Wkly. 2024; 6:767-771
10.
Xie, Y ∙ Liang, J ∙ Mu, Y ∙ et al.
Prevalence estimates of small vulnerable newborns in China (2012–22): a modelling study
Lancet Glob Health. 2026;
published online Feb 18. https://doi.org/10.1016/S2214-109X(25)00498-X
11.
Wang, D ∙ Liu, E ∙ Perumal, N ∙ et al.
The effects of prenatal multiple micronutrient supplementation and small-quantity lipid-based nutrient supplementation on small vulnerable newborn types in low-income and middle-income countries: a meta-analysis of individual participant data
Lancet Glob Health. 2025; 13:e298-e308
Facts Only
In 2022, 4.5 million maternal and newborn deaths occurred globally, with 1.9 million stillbirths and 2.3 million neonatal deaths.
Small vulnerable newborns (SVNs)—preterm, SGA, or LBW—account for up to 80% of neonatal deaths worldwide.
China’s neonatal mortality declined from 33.1 per 1,000 live births in 1990 to 3.1 in 2022.
In 2022, 65,700 children under 5 died in China, with 45.1% occurring in the neonatal period.
A 2023 Lancet Series introduced the SVN framework to address preterm birth, LBW, and SGA under one category.
Yanxia Xie et al. estimated 13.2 per 100 live births in China were SVNs in 2022.
National SVN prevalence ratios remained stable from 2012–2022 but increased after 2018.
Term SGA prevalence decreased, while preterm non-SGA and LBW-only prevalence rose.
Qinghai had the highest SVN, preterm SGA, and term SGA rates in 2022; Liaoning had the highest preterm non-SGA rate.
SVNs accounted for over 60% of in-hospital neonatal deaths and 80% of stillbirths in China.
The study calls for targeted interventions based on local epidemiological profiles.
Executive Summary
Full Take
The strongest version of this narrative is its evidence-based call for targeted interventions to address China’s SVN burden, grounded in robust epidemiological data. The study effectively bridges global health frameworks with national priorities, highlighting both progress (e.g., China’s dramatic reduction in neonatal mortality) and persistent challenges (e.g., geographic disparities and rising high-risk pregnancies). However, the framing of SVNs as a unified category—while useful for policy—risks oversimplifying distinct causal pathways. For instance, preterm non-SGA and term SGA may require different interventions, yet the narrative leans toward broad solutions like micronutrient supplementation without fully addressing structural drivers (e.g., healthcare access, socioeconomic factors).
Patterns detected: none. The analysis avoids emotional exploitation or distortion, focusing on data-driven recommendations. Yet, the root cause paradigm assumes that technical fixes (e.g., micronutrients, surveillance) can outweigh systemic issues like healthcare inequities or environmental exposures. The implications for human agency are significant: while the study empowers policymakers with actionable insights, it also risks shifting responsibility onto individuals (e.g., maternal nutrition) rather than systemic reforms.
Key questions emerge: How might China’s fertility policies (e.g., relaxed birth limits) interact with SVN trends? Could the focus on SVNs inadvertently marginalize other neonatal risks? What would a truly equitable intervention look like across provinces with vastly different resources?
If this were part of a coordinated campaign, the playbook might emphasize urgency to justify centralized policy shifts. However, the content aligns with genuine public health advocacy, not manipulation. The call for localized solutions is a healthy counterbalance to top-down approaches.
Sentinel — Human
This article appears to be written by humans. It presents an epidemiological analysis of small vulnerable newborns in China and discusses the need for targeted interventions.